Alain van Gool specializes in translational biomarkers in pharmaceutical drug development, with particular interest in personalized healthcare. His professional background is a mix of academia (1991-1998; ErasmusMC, ICRF; 2009-now, Radboud University Nijmegen), pharmaceutical industry (1999-2011; Organon, Schering-Plough, MSD), applied research institute (2011-now; TNO), and medical school (2011-now; Radboud UMC). He has lead technology-based laboratories, cross-functional biomarker expert teams, therapeutic project teams and external consortia, many of which were focused on the discovery, development and implementation of translational biomarkers in a variety of therapeutic areas.